Literature DB >> 21757844

New molecular mechanisms for cardiovascular disease: cardiac hypertrophy and cell-volume regulation.

Shintaro Yamamoto1, Satomi Kita, Takuya Iyoda, Toshiki Yamada, Takahiro Iwamoto.   

Abstract

Cardiac hypertrophy is an increase in the muscle volume of the ventricle due to the enlargement of cardiac cells. Physiological cardiac hypertrophy is the normal response to healthy exercise, and pathological hypertrophy is the response to increased stress such as hypertension. Intracellular and extracellular aniosmotic conditions also change cell volume. Since persistent cell swelling or cell shrinkage during aniosmotic conditions results in cell death, the ability to regulate cell volume is important for the maintenance of cellular homeostasis. Cell swelling activates a regulatory volume decrease (RVD) response in which solute leakage pathways are stimulated and solute with water exits cells, reducing the cell volume towards the original value. In cardiac cells, one of the essential factors for cell-volume regulation is the volume-regulated anion channel (VRAC). However, the relationship between cardiac hypertrophy and cell-volume regulation is not clear. In this review, we introduce our recent findings showing that the impairment of VRAC current is exhibited in ventricular cells from mice with cardiac hypertrophy induced by transverse aortic constriction. Similar results were shown in caveolin-3-deficient mice, which develop cardiac hypertrophy without pressure overload. These results suggest that VRAC will be a new target for protection from the development of cardiac hypertrophy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21757844     DOI: 10.1254/jphs.10r31fm

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  12 in total

1.  Sarcolemmal cholesterol and caveolin-3 dependence of cardiac function, ischemic tolerance, and opioidergic cardioprotection.

Authors:  Louise E See Hoe; Jan M Schilling; Emiri Tarbit; Can J Kiessling; Anna R Busija; Ingrid R Niesman; Eugene Du Toit; Kevin J Ashton; David M Roth; John P Headrick; Hemal H Patel; Jason N Peart
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-25       Impact factor: 4.733

2.  Gelsolin (GSN) induces cardiomyocyte hypertrophy and BNP expression via p38 signaling and GATA-4 transcriptional factor activation.

Authors:  Wei-Syun Hu; Tsung-Jung Ho; Peiying Pai; Li-Chin Chung; Chia-Hua Kuo; Sheng-Huang Chang; Fuu-Jen Tsai; Chang-Hai Tsai; Yu-Chi Jie; Ying-Ming Liou; Chih-Yang Huang
Journal:  Mol Cell Biochem       Date:  2014-02-07       Impact factor: 3.396

3.  Norcepharadione B attenuates H2O2-induced neuronal injury by upregulating cellular antioxidants and inhibiting volume-sensitive Cl- channel.

Authors:  Xin Jia; Yan Liu; Xing Li; Cong Huo; Dongtao Li; Rong Xu; Liming Hou; Xiaoming Wang
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-04

4.  Relationship between TMEM16A/anoctamin 1 and LRRC8A.

Authors:  Roberta Benedetto; Lalida Sirianant; Ines Pankonien; Podchanart Wanitchakool; Jiraporn Ousingsawat; Ines Cabrita; Rainer Schreiber; Margarida Amaral; Karl Kunzelmann
Journal:  Pflugers Arch       Date:  2016-08-12       Impact factor: 3.657

5.  Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress.

Authors:  Chi Zhang; Fan Wang; Yingxia Zhang; Yimin Kang; Haisheng Wang; Mingming Si; Liping Su; Xue Xin; Feng Xue; Fei Hao; Lechu Yu; Jinzhong Xu; Yanlong Liu; Mingming Xue
Journal:  J Cell Mol Med       Date:  2015-10-29       Impact factor: 5.310

Review 6.  Physiological and Pharmacological Roles of FGF21 in Cardiovascular Diseases.

Authors:  Peng Cheng; Fangfang Zhang; Lechu Yu; Xiufei Lin; Luqing He; Xiaokun Li; Xuemian Lu; Xiaoqing Yan; Yi Tan; Chi Zhang
Journal:  J Diabetes Res       Date:  2016-05-09       Impact factor: 4.011

7.  The Effects of Dracocephalum Heterophyllum Benth Flavonoid on Hypertrophic Cardiomyocytes Induced by Angiotensin II in Rats.

Authors:  Hong Jiang; Chen Zhang; Wen He
Journal:  Med Sci Monit       Date:  2018-09-10

Review 8.  Effects of hypertension and exercise on cardiac proteome remodelling.

Authors:  Bernardo A Petriz; Octavio L Franco
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

Review 9.  Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery.

Authors:  Paola Imbrici; Antonella Liantonio; Giulia M Camerino; Michela De Bellis; Claudia Camerino; Antonietta Mele; Arcangela Giustino; Sabata Pierno; Annamaria De Luca; Domenico Tricarico; Jean-Francois Desaphy; Diana Conte
Journal:  Front Pharmacol       Date:  2016-05-10       Impact factor: 5.810

Review 10.  Neuronal nitric oxide synthase in hypertension - an update.

Authors:  Yin Hua Zhang
Journal:  Clin Hypertens       Date:  2016-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.